Biliary Tract Cancers clinical trials

Explore recruiting biliary tract cancers clinical trials.

Recruiting biliary tract cancers studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Biliary Tract Cancers trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study.

Italy

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)

Italy, Spain, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)

Germany, Italy, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study and cost-effectivity analysis.

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

SEVILLA_A randomised, phase II trial to evaluate the efficacy of ivonescimab, a PD 1/VEGF bispecific antibody, versus FOLFOX as second line therapy for locally advanced or metastatic biliary tract cancers

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)

Poland, Bulgaria, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Biliary Tract Cancers trials by city

Biliary Tract Cancers in Toronto Biliary Tract Cancers in Vancouver Biliary Tract Cancers in Montreal Biliary Tract Cancers in Calgary Biliary Tract Cancers in Edmonton Biliary Tract Cancers in Ottawa Biliary Tract Cancers in Winnipeg Biliary Tract Cancers in Quebec City Biliary Tract Cancers in Hamilton Biliary Tract Cancers in Kitchener Biliary Tract Cancers in London Biliary Tract Cancers in Halifax Biliary Tract Cancers in New York Biliary Tract Cancers in Los Angeles Biliary Tract Cancers in Chicago Biliary Tract Cancers in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease